Bengaluru:NeoBiocon to sell anti-diabetic drug in UAE

Bengaluru, Dec 10 (IANS) NeoBiocon, a joint venture of Biocon and the Gulf-based Neopharma, is partnering with Swiss-based drug major Novartis to market its oral anti-diabetic medicines in the United Arab Emirates (UAE).

“We have tied up Novartis Middle East in Jebel Ali free zone to expand our product offerings in the metabolic segment and benefit diabetics in UAE,” Neopharma chairman B.R. Shetty said in a statement here on Thursday.

The drugs – Jalra (Vildagliptin) and Jalra-M (Vildagliptin & Metformin) – deliver blood sugar control in patients with type-two diabetes.

Total market for oral hypoglycaemic agents (OHA) in the UAE is estimated to be $115 million and DPP-IV (dipeptidyl peptidase) inhibitors command about 50 percent market share.

Vildagliptin is available as monotherapy and in combination with metformin. Both the drugs commands over 30 percent of the DPP-IV market in the UAE.

The UAE’s health ministry has approved the company’s application to market the twin drugs from January in the region.

Novartis will make the drugs in Europe and ship them to NeoBiocon for distribution in the Gulf region.

“Biocon’s leadership in the diabetes segment will augur well for marketing these brands in the UAE,” said Shetty.

Set up in 2011, the JV also markets its brands in the region & other GCC (Gulf Cooperation Council) markets in various therapies such as metabolics, oncology, asthma and allergic rhinitis.

“As we are committed to offer advanced therapies for diabetics the world over, AJalra and Jalra-M will meet the needs of type 2 diabetes patients in the UAE,” Biocon chairperson Kiran Mazumdar-Shaw added.

Leave a Reply

Please enter your comment!

The opinions, views, and thoughts expressed by the readers and those providing comments are theirs alone and do not reflect the opinions of www.mangalorean.com or any employee thereof. www.mangalorean.com is not responsible for the accuracy of any of the information supplied by the readers. Responsibility for the content of comments belongs to the commenter alone.  

We request the readers to refrain from posting defamatory, inflammatory comments and not indulge in personal attacks. However, it is obligatory on the part of www.mangalorean.com to provide the IP address and other details of senders of such comments to the concerned authorities upon their request.

Hence we request all our readers to help us to delete comments that do not follow these guidelines by informing us at  info@mangalorean.com. Lets work together to keep the comments clean and worthful, thereby make a difference in the community.

Please enter your name here